The association between genetically proxied GLP-1 receptor agonists and cancer risks.

Fei Zhou, Zhao Yang, Maoying Xing, Geng Zong, Chengwu Feng, Jing Wang, Xin Geng

Abstract read

In one paragraph

Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fei ZhouDepartment of Medical Oncology, Cancer Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Zhao YangShanghai Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.

Maoying XingShanghai Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.

Geng ZongInstitute of Nutrition, Fudan University, Shanghai, China.

Chengwu FengCAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China.

Jing WangDepartment of Respiratory Medicine, Jinshan Hospital, Fudan University, Shanghai, P. R. China.

Xin GengShanghai Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.ORCID https://orcid.org/0009-0008-7429-4706

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for type 2 diabetes and obesity, but their long-term cancer risks remain controversial in observational studies. We conducted a drug-target Mendelian randomization (MR) analysis using genetic variants in the GLP1R gene region as instruments to proxy GLP-1RA exposure. Summary-level data for 21 cancer types were obtained from public GWAS consortia. Inverse-variance weighted (IVW) MR was used as the primary method, supplemented by sensitivity analyses, Cox proportional hazards regression analyses, and mediation testing for BMI and HbA1c. Genetically proxied GLP-1RA use was associated with a reduced risk of breast cancer [the log of the odds ratio (log{OR}) = -0.343,

Indexed as

cancercohort studydiabetesdrug-target Mendelian randomizationGLP-1 receptor agonistsweight loss

Identifiers

PMID42433766

DOI10.1097/MS9.0000000000005253

PMCPMC13354389

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.